An anonymous director reports

PROMIS NEUROSCIENCES TO CONSOLIDATE TRADING ON THE NASDAQ EXCHANGE

Promis Neurosciences Inc. intends to consolidate trading of its shares on the Nasdaq Capital Market LLC exchange and, as such, has applied and received approval for a voluntary delisting of its common shares from the Toronto Stock Exchange. The last trading day on TSX will be July 21, 2023. The delisting from the TSX will not affect the company's listing on Nasdaq and the company's common shares will continue to trade uninterrupted on Nasdaq under the symbol PMN.

Promis joined Nasdaq Capital Market on July 7, 2022, and it has since become the primary market based on trading volume. The company believes that this consolidation to Nasdaq will facilitate the opportunity to undertake transactions in accordance with the rules of Nasdaq as its primary market while creating a central marketplace for common shares and providing sufficient liquidity. The company also believes that delisting from the TSX will lower the expenses of a dual listing and provide savings in time and effort of management, which can be redirected to initiatives intended to generate shareholder value.

In accordance with the requirements of the TSX company manual, shareholder approval is not required in respect of the voluntary delisting from the TSX as the company's common shares are listed on Nasdaq, which is an acceptable alternative market for the listed securities.

Most brokers in Canada, including discount and on-line brokers, have the ability to buy and sell securities listed on Nasdaq. Therefore, the company's Nasdaq listing will continue to provide shareholders with accessibility to trade the company's common shares. The value of investor shares or warrants is not related to or dependent on the listing. Shareholders holding shares or warrants in Canadian brokerage accounts should contact their brokers to confirm how to trade the company's shares on Nasdaq. Shareholders may also contact the company at info@promisneurosciences.com for assistance.

About Promis Neurosciences Inc.

Promis Neurosciences is a development-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. The company's proprietary target discovery engine applies a thermodynamic, computational discovery platform -- Promis and Collective Coordinates -- to predict novel targets known as disease-specific epitopes on the molecular surface of misfolded proteins. Using this unique approach, the company is developing novel antibody therapeutics for AD, ALS and MSA. Promis has offices in Toronto, Ont., and Cambridge, Mass. Promis is listed on Nasdaq and, effective upon the delisting, formerly the TSX under the symbol PMN.

We seek Safe Harbor.